Improving T cell function to enhance cancer immunotherapy
Modulation of asparagine bioavailability and stress response signaling to enhance T cell robustness and maximize immunotherapy
['FUNDING_R01'] · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · NIH-11017735
This study is looking at how the amino acid asparagine helps T cells, which are important for fighting cancer, work better in tough tumor environments, with the hope of improving cancer treatments that use the body's immune system.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | RESEARCH INST NATIONWIDE CHILDREN'S HOSP (nih funded) |
| Locations | 1 site (COLUMBUS, UNITED STATES) |
| Trial ID | NIH-11017735 on ClinicalTrials.gov |
What this research studies
This research investigates how the availability of asparagine, an amino acid, affects the strength and effectiveness of T cells in fighting cancer. By understanding the metabolic challenges T cells face in the tumor environment, the study aims to enhance T cell responses through better nutrient management. The approach includes examining how T cells can be supported to grow and function more effectively against tumors, potentially leading to improved outcomes in immunotherapy treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients undergoing immunotherapy for cancer who may benefit from enhanced T cell activity.
Not a fit: Patients with cancers that do not involve T cell-mediated responses may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer immunotherapies by enhancing T cell responses.
How similar studies have performed: Previous research has shown promise in enhancing T cell responses through metabolic modulation, indicating potential success for this approach.
Where this research is happening
COLUMBUS, UNITED STATES
- RESEARCH INST NATIONWIDE CHILDREN'S HOSP — COLUMBUS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: WANG, RUONING — RESEARCH INST NATIONWIDE CHILDREN'S HOSP
- Study coordinator: WANG, RUONING
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer immunotherapy, anticancer immunotherapy